Clinical Trial Search

Phase 3 N=563 A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

Low Back Pain

Primary: Change From Baseline to Week 16 in the Average Daily Low Back Pain Index Numeric Rating Scale (LBPI NRS) Score — -1.7; -2.0; -2.5; -2.4 Scores on a scale — p=0.3876

Regeneron Pharmaceuticals Results Aug 2019 2.5% serious AE View details

Phase 3 N=227 Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

Opioid Use Disorder

Primary: Subjects With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period-Overall Safety Population — 131; 12; 58; 2 participants

Braeburn Pharmaceuticals Results Aug 2019 6.6% serious AE View details

Phase 3 N=199 GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Epilepsy · Dravet Syndrome

Primary: Change In Convulsive Seizures During The Treatment Period Compared To Baseline — 48.7; 45.7; 26.9 percentage reduction — p=0.0299

Jazz Pharmaceuticals Results Aug 2019 20.2% serious AE View details

Phase 3 N=7 Allogeneic Transplantation For Severe Osteopetrosis

Severe Osteopetrosis

Primary: Number of Patients Who Achieved Donor Cell Engraftment — 5; 0 Participants

Masonic Cancer Center, University of Minnesota Results Jul 2019 42.9% serious AE View details

Phase 3 N=347 A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Alzheimer's Disease

Primary: Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score (Changes From Baseline to 14 Months) — 0.8; 0.8; 1.5; 3.2 units on a scale

Instituto Grifols, S.A. Results Jul 2019 15.8% serious AE View details

Phase 3 N=274 Extension in AS: Sustainability of Benefits, Safety and Tolerability

Spondylitis, Ankylosing

Primary: Assessment of Spondyloarthritis International Society Criteria (ASAS) 20 Response From Week 104 to Week 260 — 71.4; 80.0; 78.6; 73.0 % of responders

Novartis Pharmaceuticals Results Jul 2019 13.1% serious AE View details

Phase 3 N=325 Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Idiopathic Parkinson's Disease

Primary: Pulmonary Safety of CVT-301 Change From Baseline for FEV1. — 2.957; 3.117; -0.059; -0.078 Liters

Acorda Therapeutics Results Jul 2019 11.2% serious AE View details

Phase 3 N=452 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Anaplastic Large-Cell Lymphoma · Non-Hodgkin Lymphoma · T-Cell Lymphoma

Primary: Progression-free Survival Per Independent Review Facility (IRF) — 48.20; 20.80 months

Seagen Inc. Results Jul 2019 39.9% serious AE View details

Phase 3 N=12 A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)

Sly Syndrome · MPS VII · Mucopolysaccharidosis

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation — 12; 4; 9; 1 Participants

Ultragenyx Pharmaceutical Inc Results Jul 2019 33.3% serious AE View details

Phase 3 N=282 Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Metabolism and Nutrition Disorder · Obesity

Primary: Change in Body Weight (%) — -7.4; -4.0; -9.1; -4.8 percent change — p=0.0003

Novo Nordisk A/S Results Jul 2019 2.8% serious AE View details

Phase 3 N=819 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

Diabetes · Diabetes Mellitus, Type 2

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira — -2.42; -1.80; -1.80…

Novo Nordisk A/S Results Jul 2019 5.4% serious AE View details

Phase 3 N=792 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Dengue · Dengue Hemorrhagic Fever · Yellow Fever

Primary: Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly…

Sanofi Pasteur, a Sanofi Company Results Jul 2019 9.3% serious AE View details

Phase 3 N=250 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Dengue Fever · Dengue Hemorrhagic Fever

Primary: Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Vaccination With Either CYD Dengue Vaccine or a Placebo…

Sanofi Results Jul 2019 7.2% serious AE View details

Phase 3 N=624 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue · Dengue Hemorrhagic Fever

Primary: Percentage of Participants With Seroprotection or Booster Response After a Booster Injection (Inj.) of Diphtheria, Tetanus, Acellular Pertussis(DTaP)-Inactivated Polio…

Sanofi Pasteur, a Sanofi Company Results Jul 2019 6.1% serious AE View details

Phase 3 N=436 A Phase III Study of NK105 in Patients With Breast Cancer

Breast Cancer Nos Metastatic Recurrent

Primary: Progression Free Survival — 8.4; 8.5 months

Nippon Kayaku Co., Ltd. Results Jul 2019 14.3% serious AE View details